A study to compare the effect of Midazolam versus Dexmedetomidine in reducing myoclonus and stress response after giving Etomidate as induction agent in Laparoscopic gall bladder surgeries.

Comparative study between Dexmedetomidine and Midazolam as premedication for prevention of Etomidate-induced myoclonus and attenuation of stress response at endotracheal intubation in laparoscopic cholecystectomies. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/09/045476

Enrollment

Registered

2022-09-13

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K80- Cholelithiasis

Interventions

Intervention1: Dexmedetomidine: Injection Dexmedetomidine is to be given as infusion (0.5 microgram/kg) in 10 ml 0.9% normal saline over 10 minutes, 5 minutes before induction. Control Intervention1:

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients belonging to ASA Grade I and ASA GradeII. 2) Patients scheduled for elective laparoscopic cholecystectomy under general anaesthesia with endotracheal intubation.

Exclusion criteria

Exclusion criteria: 1) Unwilling patients. 2) Patients with anticipated difficult intubation. 3) Patients with history of known allergy to study drugs. 4) Patients with labile blood pressure, severe renal, endocrine and cardiac dysfunction, heart block. 5) Patients on Beta-blocker drugs. 6) Morbidly obese patients. 7) Patients with history of alcohol/ drug abuse. 8) Pregnant and lactating patients.

Design outcomes

Primary

Measure	Time frame
MyoclonusTimepoint: inj. Etomidae (0.3mg/kg) over 30 seconds or till the abolition of eyelash reflex will be observed	—

Secondary

Measure	Time frame
stress responseTimepoint: Heart rate, systolic blood pressure, diastolic blood pressure, mean arterial pressure and SpO2 will be measured before giving study drug (baseline); after giving study drug; before induction; after intubation; before pneumoperitoneum (P0); immediately after pneumoperitoneum; and thereafter at 10, 20, 30 and 40 minutes and after extubation.	—

Countries

India

Contacts

Public ContactMaidul Hoque

Bankura Sammilani Medical College

dr.maidul1984.mh@gmail.com7001329206

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026